FDA has approved Endari, a new treatment for sickle cell disease


The FDA ( U.S. Food and Drug Administration ) has approved Endari ( L-Glutamine oral powder ) for patients age five years and older with sickle cell disease to reduce severe complications associated with the blood disorder.

Endari is the first treatment approved for patients with sickle cell disease in almost 20 years. Until now, only one other drug was approved for patients living with this serious, debilitating condition.

Sickle cell disease is an inherited blood disorder in which the red blood cells are abnormally shaped ( in a crescent, or sickle, shape ).
This restricts the flow in blood vessels and limits oxygen delivery to the body’s tissues, leading to severe pain and organ damage.

According to the National Institutes of Health ( NIH ), approximately 100,000 people in the United States have sickle cell disease.
The disease occurs most often in African-Americans, Latinos and other minority groups.
The average life expectancy for patients with sickle cell disease in the United States is approximately 40 to 60 years.

The safety and efficacy of Endari were studied in a randomized trial of patients ages 5 to 58 years old with sickle cell disease who had two or more painful crises within the 12 months prior to enrollment in the trial.
Patients were assigned randomly to treatment with Endari or placebo, and the effect of treatment was evaluated over 48 weeks.
Patients who were treated with Endari experienced fewer hospital visits for pain treated with a parenterally administered narcotic or Ketorolac ( sickle cell crises ), on average, compared to patients who received a placebo ( median 3 versus median 4 ), fewer hospitalizations for sickle cell pain ( median 2 versus median 3 ), and fewer days in the hospital ( median 6.5 days versus median 11 days ).
Patients who received Endari also had fewer occurrences of acute chest syndrome ( a life-threatening complication of sickle cell disease ) compared with patients who received a placebo ( 8.6% vs. 23.1% ).

Common side effects of Endari include constipation, nausea, headache, abdominal pain, cough, pain in the extremities, back pain and chest pain. ( Xagena )

Source: FDA, 2017

XagenaMedicine_2017



Indietro

Altri articoli

The FDA ( U.S. Food and Drug Administration ) has approved Reyvow ( Lasmiditan ) tablets for the acute treatment...


Tthe FDA ( U.S. Food and Drug Administration ) has approved Reyvow ( Lasmiditan ) an oral medication for the...


The FDA ( U.S. Food and Drug Administration ) has approved Praluent ( Alirocumab ) to reduce the risk of...


The results from the phase 3 ADMIRAL clinical trial comparing Gilteritinib ( Xospata ) to salvage chemotherapy in adult patients...


The European Commission has approved a label update for the use of once-daily Relvar Ellipta ( Fluticasone furoate / Vilanterol,...


Acute myeloid leukemia ( AML ) remains a highly resistant disease to conventional chemotherapy, with a median survival of only...


The European Commission ( EC ) has approved Kymriah ( Tisagenlecleucel, formerly CTL019 ). The approved indications are for the...


The FDA ( U.S. Food and Drug Administration ) has approved Tibsovo ( Ivosidenib ) tablets for the treatment of...


Anthracycline-induced cardiotoxicity was first reported in early 1970s. Since then, there has been increasing recognition of its association with poor...


The FDA ( U.S. Food and Drug Administration ) has approved Xospata ( Gilteritinib ) tablets for the treatment of...